Johnson & Johnson’s (J&J) consumer healthcare department announced on Saturday a recall of over 200,000 bottles of concentrated Motrin infant drops in the market due to possible plastic contamination.
The company is requesting retailers to immediately remove the possibly contaminated half-ounce bottles of original berry flavored drops from their store display, racks, and shelves. Consumers who had already purchased Motrin should also discard their stocks and stop using those that are already open. J&J recommended the consumers to get in touch with the company about reimbursement or compensation.
Three batches are being recalled because plastic particles – as little as the poppy seed – were discovered during the manufacturing of the fourth batch of drops, which is fortunately not yet released, according to Reuters.
The company said it identified that the elements came from a shipment of a third party supplier of the active ingredient in the Motrin drops--Ibuprofen. The product is given to babies to reduce fever and relieve pain.
J&J said in a note that it has worked hand in hand with the said supplier to guarantee that remedial measures are in place, and said the use of drops is improbable to cause adverse medical effects.
In 2013 alone, the three-sector health care company has recalled millions of oral contraceptive due to faulty tablets, OneTouch VerioIQ blood glucose meters that turn off instead of displaying a warning when blood sugar levels are extremely high, Children's Tylenol manufactured in South Korea which contained high levels of acetaminophen, and many more.
It is also remembered in 2010 that the N.J-based company also recalled 40 or more non-prescription products off store displays, racks, and shelves, which includes Children’s Tylenol, following the event in which investigators have recognized problems at its plant in Fort Washington, Pennsylvania. The U.S. Food and Drug Administration has described it as the largest recall of children’s medicine in agency’s history.
The company has decided in July to compensate $22.9 million to put an end to the lawsuit from investors who asserted it obscured quality control failures.
